The Role of the Plasmalemmal Dopamine and Vesicular Monoamine Transporters in Methamphetamine-induced Dopaminergic Deficits.
From: Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA.
Journal of neurochemistry
- Publish Date: May 2007
- ISSN: 0022-3042
- Volume: 101
- Issue: 4
- Pages: 883-8
- Medium: Print
- Language: English
- Citation (JAMA): Volz Trent J, Hanson Glen R, Fleckenstein Annette E, et al. The Role of the Plasmalemmal Dopamine and Vesicular Monoamine Transporters in Methamphetamine-induced Dopaminergic Deficits.. J. Neurochem. May 2007;101:883-8
Abstract
Amphetamine (AMPH) and methamphetamine (METH) are members of a collection of phenethylamine psychostimulants that are commonly referred to collectively as “amphetamines.” Amphetamines exert their effects, in part, by affecting neuronal dopamine transport. This review thus focuses on the effects of AMPH and METH on the plasmalemmal dopamine transporter and the vesicular monoamine transporter-2 in animal models with a particular emphasis on how these effects, which may vary for the different stereoisomers, contribute to persistent dopaminergic deficits.
Mesh Headings (Keywords): Animals, Dopamine, Dopamine Plasma Membrane Transport Proteins, Dopamine Uptake Inhibitors, Humans, Methamphetamine, Vesicular Monoamine Transport Proteins
Check for Full Text / PubMed Unique Identifier (PMID): 17250674
This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.
Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.
The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.